Postreperfusion myocardial technetium-99m-sestamibi defect corresponds to area at risk: experimental results from an ischemia-reperfusion porcine model

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Abstract

Technetium-99m-sestamibi (MIBI) is the most frequently used myocardial perfusion tracer in patients with ischemic heart disease. In patients with acute ST-elevation myocardial infarction, we previously found that the defect in myocardial MIBI uptake was the same in patients injected with MIBI before primary angioplasty and in patients injected immediately after successful treatment. Thus, reperfusion may not be followed by increased uptake of MIBI. Instead, the MIBI defect after reperfusion may reflect the area at risk (AAR) defined by MIBI injected before treatment. We intended to investigate whether myocardial imaging with MIBI administered after reperfusion reflects myocardial perfusion or rather the ischemic AAR.
OriginalsprogEngelsk
TidsskriftNuclear Medicine and Biology
Vol/bind38
Nummer6
Sider (fra-til)819-25
Antal sider7
ISSN0969-8051
DOI
StatusUdgivet - 2011

Fingeraftryk

Dyk ned i forskningsemnerne om 'Postreperfusion myocardial technetium-99m-sestamibi defect corresponds to area at risk: experimental results from an ischemia-reperfusion porcine model'. Sammen danner de et unikt fingeraftryk.

Citationsformater